Merck & Co raises pressure on Pfizer in pneumococcal vaccine tussleJust a month after getting approval for its new pneumococcal vaccine Vaxneuvance in adults, Merck & Co has Share XMerck & Co raises pressure on Pfizer in pneumococcal vaccine tusslehttps://pharmaphorum.com/news/merck-raises-pressure-on-pfizer-in-pneumococcal-vaccine-tussle/
FDA okays Merck’s would-be Prevnar rival VaxneuvanceThe FDA has approved a new pneumococcal vaccine from Merck & Co, just over a month after Pfizer Share XFDA okays Merck’s would-be Prevnar rival Vaxneuvancehttps://pharmaphorum.com/news/fda-okays-mercks-would-be-prevnar-rival-vaxneuvance/
Shot in the arm for Affinivax as it challenges Pfizer’s PrevnarAlready facing one rival to its blockbuster pneumococcal vaccine Prevnar, Pfizer could have another to contend with, after Share XShot in the arm for Affinivax as it challenges Pfizer’s Prevnarhttps://pharmaphorum.com/news/shot-in-the-arm-for-affinivax-as-it-challenges-pfizers-prevnar/
FDA clears Pfizer’s Prevnar 20 for adults, as Merck rival nears decisionPfizer has the FDA approval it was seeking for Prevnar 20, the latest update to its blockbuster pneumococcal Share XFDA clears Pfizer’s Prevnar 20 for adults, as Merck rival nears decisionhttps://pharmaphorum.com/news/fda-clears-pfizers-prevnar-20-for-adults-as-merck-rival-nears-decision/
Adult data back Merck & Co’s challenger to Pfizer’s blockbuster Prevnar 13Merck & Co has built more momentum behind its attempt to depose Pfizer’s blockbuster pneumococcal conjugate vaccine Prevnar Share XAdult data back Merck & Co’s challenger to Pfizer’s blockbuster Prevnar 13https://pharmaphorum.com/news/adult-data-back-mercks-challenger-to-pfizers-blockbuster-prevnar-13/
